Skip to main content
WeLoveTrump.com may receive compensation from affiliate partners for some links on the site. Read our full Disclosure here.

Pfizer Conducting Trials for a Single Pill COVID “Cure” to be Ready in 2021?


3,948 views

If there’s one thing you can count on during a virus, it’s for Big Pharma to make a hefty profit.

We’re now four months into the global rollout for the COVID-19 experimental vaccines and Pfizer has provided millions of those jabs.

They’ve already made a massive profit from COVID-19 vaccines and are expected to rake in 3-4 times as much dough as last year.

After racing these experimental jabs to the public with 2-month safety trials and coercing foreign governments to be waived of all liability, Pfizer unveiled another project in the works.

An antiviral drug that supposedly can cure COVID-19 by orally ingesting a single pill.

Here’s the latest:

Let me get this straight, they’re conducting regular clinical trials for an antiviral drug but chose to rush trials for vaccines.

And with mRNA vaccines that have never been used on the public.

Plus, they wait until millions of their doses have already been injected before announcing this “miracle” cure.

Don’t get me wrong, I hope this treatment is successful and becomes a literal cure for COVID-19.

But I know we’ve already had viable treatments available for months that have been suppressed by the lamestream media to help Big Pharma rake in their billions.

The timing of this miracle drug seems sketchy and too convenient for Pfizer.

The Blaze provided more info:

Pfizer CEO and chairman Albert Bourla says that the biopharmaceutical company behind the COVID-19 vaccine could publicly release an antiviral drug designed to treat the coronavirus by the end of 2021.

Bourla on Monday told CNBC’s “Squawk Box” that the drug — called PF-07321332 — is an antiviral drug intended for oral ingestion in COVID-19-positive patients when the illness is first detected. The company is also testing an intravenous option.

The treatment is anticipated to be effective against varying strains of the deadly virus.

Bourla said that the company is zeroing in on the oral option as it “provides several advantages” and can be taken in the comfort of the patient’s home. The option, he added, would be a “game-changer.”

“The compound that we are talking about and you said very well the numbers, it is a protease inhibitor,” he explained. “The good thing is that this is also the first molecule that is coming from this type of class, this is good thing because you can combine it with other classes. Also, the mechanism of action, it is such that it’s not expected to be subject to mutations, particularly because it’s not acting on the spike, as we all know, all the mutations that we are hearing right now are seeing this in the proteins of the spike.”

“This one doesn’t work there so that allows us to believe that will be way more effective against the multiple variants,” Bourla added. “So, all good news. We are now progressing the studies and we will have more news around summer.”

Bourla added that he hopes the drug could be released to the public by the end of 2021.

“[I]f all goes well, and we implement the same speech that we did so far and we are and if regulators also do the same and they are, I hope by the end of the year,” he said.

The company in March announced it had begun Phase 1 clinical trials of the antiviral treatment.

From a Tuesday Forbes report:

Pfizer announced late last month they had begun Phase 1 clinical trials of the drug, called PF-07321332. Its effectiveness is due to protease inhibitors in the drug that bind to viral enzymes, preventing viruses from replicating in the cell. “Tackling the Covid-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus,” said Mikael Dolsten, Pfizer’s chief scientific officer, in a press release. “Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic.” According to Pfizer, protease inhibitors have proven effective in combating other viral pathogens such as HIV and hepatitis C.

And from the New York Post:

“We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care,” Mikael Dolsten, who leads the company’s worldwide research, development and medical division, said in a statement.

Trials are already underway with volunteers between the ages of 18 and 60 in the US and Brussels, the newspaper reported.

“If they have moved to this stage, they will be quietly optimistic,” Dr. Penny Ward, a visiting professor in pharmaceutical medicine at King’s College London, told the Telegraph.

The drug company said the first phase of the trial is designed to look at how the drug is tolerated, in addition “significant side effects, and how people feel after taking it,” according to documents obtained by the newspaper.

The second phase will study how participants react to multiple doses, while the third will look at the impact of eating while on the drug, the outlet reported.

More trials would be needed to determine how the drug works with people infected with COVID-19, the newspaper reported.

If the results of the trials are promising, the oral medication could be available later this year, the outlet reported.

Wow! Look at Pfizer’s newfound concern for running multi-phased safety trials to study potential side effects.

Where was that concern with mRNA vaccine technology that’s never been used on the public before?

As previously mentioned, I hope this drug turns out to be a viable therapeutic for patients.

But waiting four months into a global vaccine rollout to announce it just shows that Big Pharma is playing their cards for a monopoly on COVID-19 treatments.

Tell us your thoughts on these developments.



We Love Trump
Thanks for sharing!
Send this to a friend